Introduction
============

Despite plasticity of the central nervous system is considered a positive adaptive phenomenon related to structural modifications as well as changes in afferent inputs and target outputs, sometimes it may become detrimental causing significant dysfunctions. In this case, functional impairment is the result of maladaptive plasticity ([@B83]).

The best example of maladaptive plasticity in human pathology is focal dystonia where sensory motor plasticity impairment occurs as a consequence of excessive practicing of a stereotyped movement leading to musician's dystonia or writer's cramp ([@B88]).

Non-invasive brain stimulation (NIBS) has a therapeutic potential in focal dystonia, as revealed by clinical studies that have demonstrated the efficacious and long-lasting neuromodulatory effects of repetitive transcranial magnetic stimulation (rTMS) at 1 Hz over primary somatosensory area (S1; [@B34]) and rTMS at 0.2 Hz or 1 Hz over the premotor cortex ([@B69]; [@B12]).

Chronic pain is another classic example of maladaptive plasticity in neurology and provides the ideal model to discuss the use of NIBS in the prevention of this pathological event.

Therefore, in the present review, we would like to discuss the potential role of NIBS in blocking and possibly reverting maladaptive plasticity, which is associated with several models of chronic pain, such as central post-stroke pain, pain after spinal cord injury or post-surgical pain.

Maladaptive Plasticity in Chronic Pain
======================================

The detection of noxious stimuli ([@B96]) is a protective process that helps to prevent injury by generating both a reflex withdrawal from the stimulus and a sensation so unpleasant that culminates in complex behavioral strategies to avoid further contact with such noxious stimuli. If stimuli are particularly intense, sensitization of the nociceptive system may lower the threshold for nociception, increasing the amplitude of withdrawal responses to subsequent inputs ([@B118]). In this sense, nociceptor-induced sensitization of the somatosensory system is a very efficient adaptive plastic mechanism that makes the system hyper alert in conditions in which a risk of further damage is high, for example, immediately after exposure to an intense or damaging stimulus.

In many clinical syndromes, pain is no longer protective. The pain in these situations arises spontaneously, can be elicited by normally innocuous stimuli (allodynia), is exaggerated and prolonged in response to noxious stimuli (hyperalgesia), and spreads beyond the site of injury (secondary hyperalgesia). Overstimulation of nociceptive pathways induced by chronic conditions (such as inflammatory pain, neuropathic pain, or deafferentation syndromes) in predisposed patients (depending on the influence of the individual genotype on the predisposition to pain chronicity and, consequently, the response to treatment; [@B6]) may lead to a massive maladaptive re-arrangement in pain-related structures, called central sensitization, which culminates in secondary hyperalgesia and allodynia. When neurons in the dorsal horn of spinal cord are subject to central sensitization, they develop: (i) an increase in spontaneous activity; (ii) a reduction in the threshold for activation by peripheral stimuli; (iii) an increase in response to supra-threshold stimulation; and (iv) an enlargement of their receptive fields ([@B117]; [@B118]; [@B40]). Central sensitization induces conversion of nociceptive-specific neurons to wide-dynamic-range neurons that now respond to both innocuous and noxious stimuli ([@B114], [@B115]).

In this way, spinal dorsal horn neurons undergoing central sensitization become hyper-excitable and hyper-responsive to nociceptive inputs from already sensitized or injured first order neurons. They also show hyper-responsiveness to inputs from other non-sensitized neurons outside the lesioned area (secondary hyperalgesia) and become responsive to non-nociceptive inputs to the nociceptive pathway (allodynia; [@B116]).

At molecular level, central sensitization of pain is characterized by two different phases: (i) the phosphorylation-dependent stage, resulting in rapid changes of glutamate receptors and ion channel properties. This stage is induced with a short latency (seconds) by intense, repeated, or sustained nociceptor inputs and typically lasts from tens of minutes to several hours in the absence of further nociceptor input. (ii) the transcription-dependent stage, where synthesis of new proteins take place for longer-lasting effects. Both these stages depend on N-methyl-D-aspartate (NMDA) receptors and glutamate signaling modifications and contribute to the induction and maintenance of acute activity-dependent central sensitization ([@B121]). Multiple triggers can contribute to the establishment of this process, such as substance P, Calcitonin Gene Related Peptide (CGRP), bradykinin, Brain-Derived Neurotrophic Factor (BDNF), and nitric oxide ([@B49]). Indeed, these different triggers are released or induced in response to nociceptor activity, and each trigger can initiate the activation of multiple intracellular signaling pathways that lead to a hyperexcitability in dorsal horn neurons. The elevation in intracellular Ca^2+^ has a key role since it activates multiple Ca^2+^-dependent kinases acting on receptors and ion channels, which increases synaptic efficacy.

Finally, glutamate receptor phosphorylation during central sensitization increases the activity/density of NMDA receptors, leading to an increase in membrane excitability, a facilitation of synaptic strength, a decrease in inhibitory influences in dorsal horn neurons, and the strengthening of nociceptive transmission at the dorsal horn. The role of glutamate in central sensitization is suggested by animal studies that have revealed that NMDA receptor blockade by microinjection of 2-amino-5-phosphonopentanoate in the rostral ventromedial medulla (RVM) attenuated signs of central sensitization ([@B15]; [@B107]). Similarly, microinjection of MK-801 (a NMDA receptor antagonist) within the thalamus reduces signs of central sensitization ([@B43]; [@B41]). The NIBS-induced plasticity modulation is achieved though several mechanisms, including changes in threshold, in kinetics and trafficking to the membrane of glutamate receptors, increase in inward currents and reduction in outward currents of ion channels, and reduction in inhibitory neurotransmission. Altogether, such mechanisms may lead to changes in the excitability of nociceptive neurons ([@B14]; [@B23]).

On the other hand, transcription-dependent changes are required for longer-lasting effects; these do not occur only in response to nociceptor activity but also as a consequence of peripheral inflammation and nerve injury (see below). In this stage, different mechanism of synaptic plasticity with some resemblance to long-term potentiation (LTP) and long-term depression (LTD) phenomena occur in central nervous system, thus activating either active synapses (homosynaptic potentiation) or non-activated synapses (heterosynaptic potentiation). The main mediators of these mechanism are thought to be the metabotropic glutamate receptors and the nitroxide ([@B22]).

Even though the role of neural circuit remodeling and structural synaptic plasticity in the "pain matrix" in chronic pain has been thought as a secondary epiphenomenon to altered nociceptive signaling in the spinal cord, brain imaging studies on human patients and animal models have suggested the possibility that structural plastic changes in cortical neural circuits may actively contribute to the development of chronic pain symptoms ([@B44]). Indeed, activity-dependent central sensitization is basically an adaptive mechanism, since it prevents, e.g., the use of an injured body part. Nonetheless, central sensitization is pathological when tissue damage persists or if it becomes autonomous and it is maintained in absence of real signaling ([@B48]).

At central level, the abovementioned plastic changes indeed occur in at least six supra-spinal structures of the pain matrix, including the primary somatosensory cortex (S1), secondary somatosensory cortex (S2), anterior cingulate cortex (ACC), insular cortex, and thalamus, which are involved in the phenomena of central sensitization ([@B108]; [@B128]). In addition, neuroimaging studies of induced secondary hyperalgesia have shown significant activations in the prefrontal cortex, periaqueductal gray (PAG), nucleus cuneiformis, superior colliculi, cerebellum and somatosensory and parietal associative cortices ([@B38]; [@B7]; [@B113]; [@B62]; [@B124]; [@B51]; [@B94]). On the other hand, pathological and experimentally induced allodynia appear to be associated with enhanced activity of ACC, thalamus, RVM, PAG, insula, orbitofrontal cortex, dorsolateral prefrontal cortices (DLPFCs), putamen, somatosensory cortex, and dorsomedial midbrain. These supra-spinal structures may exert facilitatory pain mechanisms that have been implicated in the generation and maintenance of central sensitization and, possibly, the establishment of chronic pain ([@B60], [@B61]; [@B9]; [@B63]; [@B95]; [@B33]).

By a molecular point of view, the NMDA-mediated mechanisms of central sensitization also contributes to the longer-lasting and sometimes persistent pain hypersensitivity ([@B49]). With regard to neuropathic pain, damaged and non-damaged Adelta- and C-fiber generate spontaneous action potentials after a peripheral nerve injury (ectopic input; [@B19]; [@B20]). Such activity in C- and also Adelta-fiber can initiate and maintain activity-dependent central sensitization in the dorsal horn ([@B47]; [@B18]). Injured and also non-injured sensory neurons in the dorsal root ganglion exhibit massive changes in transcription, thus altering their membrane properties, growth, and transmitter functions ([@B122]). Affected fibers express new transmitters and neuromodulators, including substance P, BDNF, and a cofactor for nitroxide synthase (namely, synthetic enzymes for tetrahydrobiopterin). On the other hand, the stimulation of non-nociceptive fibers triggers the release of factors that can further drive central sensitization ([@B122]). The release of these mediators induces a substantial disinhibition in the dorsal horn with loss of Gamma-Aminobutyric-Acid(GABA)ergic and glycinergic inhibitory currents leading to a NMDA-dependent excitotoxicity neuronal death ([@B68]; [@B93]). In addition, there is also an increase in descending excitatory controls from the RVM in the brainstem after peripheral nerve injury, as well as a reduction of descending inhibitory controls ([@B109]).

Of note, there are also structural changes as a consequence of the molecular processes described above, which consist in a trans-ganglionic degeneration of C-fiber terminals in lamina II. This degeneration determines the myelinated Abeta-fibers sprouting from laminae III-IV into laminae I-II and making contact with nociceptive-specific neurons ([@B119], [@B120]). Finally, astrocytes become hyper-active after nerve injury and may play a role in the maintenance of neuropathic pain hypersensitivity ([@B127]).

It is likely that chronic pain, regardless of the etiology (inflammatory or neuropathic) and pain model, may trigger various forms of maladaptive structural plasticity at cortical and sub-cortical level, which in turn could be directly or indirectly involved in the development of sensory, emotional and cognitive symptoms of chronic pain. Since it is well known that structural plasticity of neuronal connections in the brain occurs after a period of several weeks or months after the functional changes, it is mandatory in the future, to intervene as soon as possible before these permanent changes may take place. In this perspective, the use of NIBS in the transition from acute to chronic pain should be explored in the near future to optimize a time window for new efficient therapeutic strategies ([@B2]).

General Overview on Non-Invasive Brain Stimulation and Cortical Plasticity: TMS and Transcranial Direct Current Stimulation (tDCS)
==================================================================================================================================

TMS and tDCS are methods to painlessly stimulate the cerebral cortex through the intact skull, and can be used to induce long-term effects in several cortical areas.

TMS was conceived as a method to investigate the integrity of the corticospinal outflow from cerebral motor cortex to the spinal cord ([@B91]). Indeed, TMS pulses readily penetrate the skull and carry an electric stimulating current into the cortex near the surface, thus activating the axons of interneurons of layers II and III that synapse onto the pyramidal neurons of layers V. In this way, the size of the response produced by a given stimulus is sensitive to the excitability of synaptic connections within the cortex, giving an indirect measure of the excitability of intrinsic cortical circuits within the conscious brain. This provides a reliable indicator of any changes produced by neural plasticity within the motor cortex. In addition, when probing motor cortex excitability with single pulses, TMS can also produce long-term changes in excitability if the TMS pulses are applied repetitively ([@B98]). In general, low-frequency stimulation (1 Hz or below) depresses cortical excitability, whereas high-frequency application (5 Hz) increases cortical excitability ([@B86]). Although the duration of the effects of brief rTMS is short-lasting, longer-lasting after-effects can be achieved by using protocols that include longer periods of stimulation or multiple sessions of rTMS ([@B88]).

Most researchers believe that the long-lasting therapeutic effects of rTMS and the effects of magnetic stimulation on the processes described above are related to two phenomena: LTP and LTD ([@B129]). The possibility that rTMS induces changes in brain excitability that outlast the stimulation period has prompted its use for therapeutic purposes. The long lasting effects are probably mediated through NMDA synaptic plasticity. Indeed, it has been demonstrated that the long lasting after effects of continuous and intermittent theta burst stimulation on the M1 of healthy volunteers are abolished by using memantine, an NMDA-receptor antagonist ([@B37]). According to the classical model of induction of LTP- and LTD-like effects, postsynaptic NMDA receptors induce Ca^2+^ influx into neurons. This ionic shift triggers a series of reactions that prompt long-term changes in synaptic strength ([@B64]). An important upstream regulator of NMDA synaptic plasticity is the BDNF- Tropomyosin receptor kinase-B (TrkB) system. Indeed, we showed that a 5-day rTMS stimulation enhanced BDNF binding affinity for TrkB, BDNF-TrkB signaling, and NMDA receptor-TrkB interaction in rat prefrontal cortex ([@B111]). Interestingly, in the same study, we showed that the same protocol could induce an increased BDNF binding affinity for TrkB and enhanced BDNF-TrkB signaling in rats and humans peripheral lymphocytes ([@B111]). These results suggest that the long lasting excitatory effects of rTMS are at least in part mediated through an upstream regulation of glutamatergic NMDA interaction.

Another important issue about the mechanism of action of rTMS at a system level is that the effects of rTMS are not only restricted to the stimulated region but tend to spread over distant interconnected cortical, subcortical, and spinal structures ([@B46]). This possibility opens a window to reach subcortical structures of the pain matrix that are involved in the mechanism of central sensitization. Indeed, neuroimaging studies have revealed that rTMS applied over the primary motor cortex (M1) can modulate the activity in cortical and subcortical regions such as M1, premotor cortex supplementary motor area, thalamus, ACC, somatosensory cortex, insula, red nucleus, and cerebellum ([@B27]; [@B97]; [@B8]; [@B50]; [@B82]; [@B100]; [@B101]; [@B92]; [@B32]; [@B13]). Similarly, DLPFC, ACC, somatosensory cortex, basal ganglia, thalamus, insula, cerebellum and parahippocampus were the main targeted areas when rTMS was applied over DLPFC ([@B126]; [@B84]; [@B59]; [@B66]; [@B24]).

tDCS does not induce any action potential, in contrast to other NIBS techniques. It instead modulates membrane excitability by the application of weak electrical currents through two oppositely charged electrodes. The amount of polarization is small, but it can bias the membrane potential of cells, changing the threshold for synaptic activation. When a positively charged electrode (anode) is applied to the surface of the scalp, a fraction of the current is thought to enter the brain and to polarize neurons in proximity of the electrode, thus increasing neuronal firing. Conversely, a negatively charged electrode (cathode) decreases cortical excitability and induces neuronal hyperpolarization ([@B77]; [@B88]).

Application of a small current (1--2 mA), using two electrodes on the scalp for 5--10 min, changes cortical excitability up to 30--60 min afterward ([@B77]). Animal experiments show that this leads to changes in firing rates of neurons while the stimulus is applied, and it is thought that this causes long-term effects on excitability that outlast the stimulation ([@B31]). Similar to the effects of rTMS, after-effects of tDCS are abolished by NMDA receptor antagonists and, hence, are likely to reflect changes in synaptic effectiveness ([@B74]). In addition to NMDA receptors, it is also possible that dopamine and GABA receptors are involved in tDCS-mediated neuroplasticity. Indeed the administration of sulpiride (a D2 receptor antagonist) abolishes tDCS after-effects in normal humans ([@B75]). In addition, lorazepam enhances and prolongs the plastic effects of anodal tDCS ([@B76]). Finally, the effects of tDCS can also be non-synaptic, possibly involving transient changes in the density of protein channels localized below the stimulating electrode or alterations on cAMP and calcium levels ([@B73]). Indeed, the tDCS-induced constant electric field can locally change ionic concentrations, induce a migration of transmembrane proteins (similarly to gel electrophoresis), thus causing steric and conformational changes, and locally alter the tissue acid--base balance ([@B5]). The latter may mainly affect NMDA signaling ([@B103]).

Putative Mechanisms of TMS in Pain Treatment
============================================

Best practices for neurostimulation on neuropathic pain have been standardized and are available in the European Federation of Neurological Societies for neurostimulation therapy for neuropathic pain ([@B16]). Nonetheless, it is difficult to determine which specific parameters are best for clinical use, since the TMS treatment parameters vary among the published studies. Effectiveness of rTMS depends on the type of neuropathic pain ([@B52]; [@B58]), although many types of intractable chronic pain have been treated with NIBS. On note, before rTMS can be applied in a patient, it is necessary to accurately determine timing, amount, and duration for each stimulation session, thereby ensuring the optimal duration of effect. Significant results have been reported when employing rTMS at 20 Hz ([@B30]; [@B58]). Nonetheless, rTMS has also been tested at low-frequency stimulation (1 Hz), thus reducing the activity of excitatory circuits in the human motor cortex. However, the best frequency of stimulation for the most effective pain treatment has not yet been resolved. The most commonly targeted area is represented by the M1 contralateral to the position corresponding to the somatotopic location of the pain source; the DLPFC is also of interest, since it seems to have a substantial influence on neuronal circuits involved in the processing of cognitive and emotional aspects of pain ([@B89]).

Beyond frequency and protocol duration, the orientation of the figure-of-eight--shaped coil used to perform the stimulation can influence the nature of the descending volleys elicited by the TMS itself. It is well known that the best analgesic effect is obtained using an antero-posterior orientation ([@B3]). Taking into account the effects of magnetic field orientation on cortical fibers, pain relief after stimulation of M1 is thought to be produced by activating fibers running superficially within the precentral gyrus, parallel to the convexity of the cortical surface. This pattern of activation is similar to that produced by cathodal epidural motor cortex stimulation (EMCS) at the crown of the precentral gyrus.

Another important issue when designing a NIBS protocol for pain treatment is the timing of rTMS application. It is generally thought that rTMS should be applied as soon as possible in case of intractable pain ([@B105]).

There are many uncertainties regarding the mechanism of pain relief induced by TMS and the nature and connections of the TMS-activated neuronal circuits ([@B72]). It is thought that NIBS may target the 'top--down' regulatory system controlling anti-nociception. TMS may induce a variety of changes concerning LTD and LTP mechanisms, activation of feedback loops, and changes in neuronal excitability. In fact, neurostimulation can activate axons more easily than cell bodies ([@B79]) and, therefore, the mechanisms of action of neurostimulation must be modeled in terms of neural circuits rather than local brain activity changes. Axons recruited by cortical stimulation can be short fibers of intracortical interneurons of layers II and III and afferent or efferent fibers connected with distant structures. Altogether, these changes may decrease sensory pain threshold and inhibits the transmission of sensory information in the spinothalamic tract, depending on the stimulation duration and frequency of each treatment ([@B57]; [@B53]).

Of note, the fact that motor but not sensory cortex stimulation relieves pain is not fully understood. Since TMS only directly affects the superficial cortex, the currents rapidly dissipate, the triggered action potentials propagate to distributed neural networks, and M1 projections directly reach pain-modulating structures (including medial thalamus, anterior cingulate/orbitofrontal cortices, and PAG), it is possible that parallel fibers within motor areas may be more suitable than the sensory ones to be targeted by TMS ([@B39]; [@B112]; [@B70]; [@B85]). Indeed, experimental evidence suggests that either epidural stimulation or NIBS may act through an antidromic modulation of the thalamo-cortical pathways ([@B106]), thus confirming the important role of the connections between afferent fibers from thalamic nuclei and pyramidal cells concerning nociception control ([@B110]). In keeping with this notion, recent studies confirmed that the integrity of the thalamo-cortical tract is required to mediate the anti-nociceptive effects of high-frequency rTMS of M1 ([@B81]). In addition, there is evidence suggesting that rTMS may exert a descending modulation within the brainstem, triggered by the cortico-thalamic output ([@B57]).

Finally, it should be considered that rTMS of M1 also can act on structures involved in the affective, cognitive, and emotional aspects of pain, such as the cingulate, prefrontal, and orbitofrontal cortices involving opioidergic mechanisms ([@B102]). In line with this view, an elevation of serum beta-endorphin concentration was found in patients with phantom limb pain successfully treated by high-frequency rTMS of M1 ([@B1]). Last, naloxone (an opioid receptor antagonist) significantly reduces the analgesic effect of high-frequency rTMS on either M1 or left DLPF in normal volunteers ([@B17]; [@B104]). Regarding the neurotransmitters, the mechanisms of action of motor cortex stimulation could also involve inhibitory GABA transmission. This is suggested by some data reporting that intracortical inhibition, a TMS marker of GABA~A~ transmission in the motor cortex, is reduced in the hemisphere contralateral to neuropathic pain. High-frequency rTMS of M1 can restore intracortical inhibition in correlation with the amount of induced pain relief in patients with neuropathic pain ([@B56], [@B55]; [@B25]; [@B65]).

Putative Mechanisms of tDCS in Pain Treatment
=============================================

As compared to TMS, tDCS after-effects are less well characterized ([@B71]). There is growing evidence confirming the effectiveness of tDCS in treating different types of neuropathic pain ([@B45]), including refractory orofacial pain, fibromyalgia, phantom pain, and back pain ([@B90]; [@B11]; [@B125]). Several papers have used different sites of stimulation, including the DLPFC and M1 ([@B28],[@B29]; [@B80]), intensity of stimulation (1--2 mA), time (from 10 up to 30 min; [@B10]) and duration of application (i.e., number of sessions per week; [@B99]).

The mechanism of action of tDCS differs from that of rTMS or epidural motor cortex stimulation, since tDCS-induced current intensity is not high enough to generate action potentials into the brain by itself alone ([@B54]). As outlined above, tDCS increases or decreases the value of axon membrane potential (depolarization or hyperpolarization), according to the polarity (anodal or cathodal) of the stimulation. However, tDCS may exert local and remote effects that, like rTMS, extend well beyond the time of stimulation, reversibly, painlessly, and safely ([@B78]).

Similarly to EMCS and rTMS, the analgesic effects of tDCS may result from the modulation of distant neural structures involved in sensory-discriminative, cognitive, or emotional aspect of chronic pain ([@B123]). Indeed, tDCS has preferential analgesic efficacy when the motor cortex receives anodal stimulation, whereas EMCS-induced analgesia is mediated by the placement of cathode over M1 ([@B36]; [@B26]). This is supported by a recent study showing decreased levels of glutamate in the ACC and thalamus and increased levels of N-acetyl-aspartate and GABA in the posterior and anterior insula after anodal tDCS delivered over the left M1 in patients with non-neuropathic pain ([@B21]). In addition, similarly to rTMS, tDCS may also target the opioid system. In particular, the posterior thalamus was activated by anodal tDCS of M1 in a patient with trigeminal neuropathic pain ([@B35]).

Expert Commentary and Future Perspectives
=========================================

In line with the current lines of research, we hypothesize that NIBS over M1 could exert its modulation of descending facilitatory pathways and the subsequent disruption of ongoing plastic changes in cortical and sub-cortical structures of the pain matrix, before they consolidate in maladaptive structural phenomena.

Considering that central sensitization is a mechanism mediated by NMDA related synaptic plasticity, it is tempting to consider the possibility of using rTMS at early stages to shift the threshold of plasticity and to trigger homeostatic mechanisms that could reset abnormal plasticity and may prevent the development of maladaptive plasticity phenomena.

In line with this hypothesis, one opportunity of manipulating the abnormal plasticity in acute pain would be to prime the effects of rTMS. Indeed, preconditioning M1 using tDCS prior to 1 Hz rTMS of M1 effectively modulated experimental thermal pain thresholds. In addition, the direction of pain threshold modulation after 1 Hz rTMS depended on the polarity of tDCS priming. For the cathodal (inhibitory) tDCS before 1 Hz rTMS, heat and cold pain thresholds significantly increased. Consistently with the concept that pre-conditioning with tDCS controls the direction of the effect of subsequent rTMS, pain threshold decrease was observed after the anodal (excitatory) tDCS before 1 Hz rTMS ([@B67]).

Further studies are needed to provide direct evidence of the efficacy of NIBS to prevent the development of maladaptive plasticity at an early stage, using the prime technique. In particular, it would be important to evaluate the homeostatic control of plasticity in patients with neuropathic pain, especially in the acute phase, in order to better define the priming protocol of stimulation.

It is interesting to note that patients suffering from migraine have an alteration of the homeostatic regulation plasticity within the motor cortex between the attacks ([@B4]), similarly to patients with focal dystonia, another condition characterized by maladaptive plasticity ([@B87]; [@B42]).

Finally, since there are no reliable serum biological markers that can assess neuroplasticity, it will be useful to validate surrogate outcomes for neuroplasticity using TMS, high-density electroencephalography, and neuroimaging methods (including tractography), in the attempt to better correlate functional and structural maladaptive plastic changes with clinical outcomes.
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